Market Overview

UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following Management Meeting

Related ARNA
What's Driving Orexigen Therapeutics Higher?
Arena Pharmaceuticals Reports Q3 Loss, Shares Surge 6%

In a report published Monday, Credit Suisse analyst Lee Kalowski reiterated an Underperform rating on Arena Pharmaceuticals (NASDAQ: ARNA), but lowered the price target from $5.00 to $4.00.

In the report, Credit Suisse noted, “As Q3 closes and following a Friday meeting with management, we are lowering our Belviq US net sales estimate for Q3, Q4, and each year through 2018 (2019-2020 are unchanged). We expect consensus will be coming down in the weeks ahead. We think a capital raise may potentially be required next year and have built this into our model. With these changes, our DCF-derived target price goes from $5 to $4.”

Arena Pharmaceuticals closed on Friday at $5.79.

Latest Ratings for ARNA

DateFirmActionFromTo
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & CompanyInitiates Coverage onMarket Perform
Oct 2013Piper JaffrayMaintainsOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Credit Suisse Lee KalowskiAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARNA)

Around the Web, We're Loving...

Get Benzinga's Newsletters